Results 321 to 330 of about 69,031,262 (351)

Remdesivir for the treatment of COVID-19

Cochrane Database of Systematic Reviews, 2023
Remdesivir is an antiviral medicine approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19). This led to widespread implementation, although the available evidence remains inconsistent. This update aims to fill current knowledge gaps by identifying, describing, evaluating, and synthesising all evidence from randomised ...
Felicitas, Grundeis, Kelly, Ansems, Karolina, Dahms, Volker, Thieme, Maria-Inti, Metzendorf, Nicole, Skoetz, Carina, Benstoem, Agata, Mikolajewska, Mirko, Griesel, Falk, Fichtner, Miriam, Stegemann   +10 more
openaire   +2 more sources

Molnupiravir for the treatment of COVID-19

Drugs of Today, 2022
Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metabolic processes. NTP inhibits viral polymerase by acting as an alternative substrate.
Bela G, Santani, Brian W, LeBlanc, Ritesh P, Thakare   +2 more
openaire   +2 more sources

Remdesivir for the treatment of COVID-19

Cochrane Database of Systematic Reviews, 2021
Remdesivir is an antiviral medicine with properties to inhibit viral replication of SARS-CoV-2. Positive results from early studies attracted media attention and led to emergency use authorisation of remdesivir in COVID-19.  A thorough understanding of the current evidence regarding the effects of remdesivir as a treatment for SARS-CoV-2 infection ...
Kelly, Ansems, Felicitas, Grundeis, Karolina, Dahms, Agata, Mikolajewska, Volker, Thieme, Vanessa, Piechotta, Maria-Inti, Metzendorf, Miriam, Stegemann, Carina, Benstoem, Falk, Fichtner   +9 more
openaire   +2 more sources

Colchicine for the treatment of COVID-19

Emergencias, 2021
The development of severe coronavirus disease 2019 (COVID-19) and poor clinical outcomes are associated with hyperinflammation and a complex dysregulation of the immune response. Colchicine is an anti-inflammatory medicine and is thought to improve disease outcomes in COVID-19 through a wide range of anti-inflammatory mechanisms.
Agata, Mikolajewska, Anna-Lena, Fischer, Vanessa, Piechotta, Anika, Mueller, Maria-Inti, Metzendorf, Marie, Becker, Elena, Dorando, Rafael L, Pacheco, Ana Luiza C, Martimbianco, Rachel, Riera, Nicole, Skoetz, Miriam, Stegemann   +11 more
openaire   +3 more sources

Tocilizumab for the treatment of COVID-19

Expert Review of Anti-infective Therapy, 2023
Since the beginning of the COVID-19 pandemic, the repurposing of medicines has been pursued to find interventions effective in preventing fatal outcome of the disease. One of these drugs was tocilizumab, an interleukin-6 inhibiting monoclonal antibody, previously used to treat several immune-related disorders.In this article, we present the results of ...
Robert Flisiak, Marta Flisiak-Jackiewicz, Piotr Rzymski, Dorota Zarębska-Michaluk   +3 more
openaire   +2 more sources

Ivermectin Treatment for Covid-19

New England Journal of Medicine, 2022
Romain, Barus, Sophie, Gautier, Guillaume, Wabont   +2 more
openaire   +4 more sources

New Studies Examine COVID-19 Risks Among Cancer Patients

Ca-A Cancer Journal for Clinicians, 2022
Mike Fillon
exaly  

Cancer Treatment Delays Caused by the COVID-19 Pandemic May Not Hinder Outcomes

Ca-A Cancer Journal for Clinicians, 2021
Mike Fillon
exaly  

Planning for Post-Pandemic Cancer Care Delivery: Recovery or Opportunity for Redesign?

Ca-A Cancer Journal for Clinicians, 2021
Kathryn A Gold, Hope Rugo, Pelin Çınar
exaly  

Long COVID: Major Findings, Mechanisms and Recommendations

Nature Reviews Microbiology, 2023
Julia M. Vogel, Hannah E. Davis
exaly